Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
4D Molecular Therapeutics, Inc. FDMT
$17.82
+$0.97 (5.44%)
На 18:04, 12 мая 2023
+113.24%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
571820219.00000000
-
week52high
26.49
-
week52low
5.32
-
Revenue
3129000
-
P/E TTM
-5
-
Beta
2.48700800
-
EPS
-3.48000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Outperform | 12 авг 2022 г. |
| Jefferies | Buy | 22 июн 2022 г. | |
| SVB Leerink | Outperform | Outperform | 13 мая 2022 г. |
| Goldman Sachs | Neutral | 05 янв 2021 г. | |
| B of A Securities | Buy | 05 янв 2021 г. | |
| Jefferies | Buy | 29 авг 2022 г. | |
| HC Wainwright & Co. | Buy | 18 ноя 2022 г. | |
| Goldman Sachs | Buy | Neutral | 15 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 14 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 10 ноя 2022 г. |
| BMO Capital | Outperform | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kirn David | D | 1893599 | 8625 | 20 янв 2023 г. |
| Kirn David | D | 1902224 | 10899 | 19 янв 2023 г. |
| Moretti August J | D | 220060 | 3000 | 21 дек 2022 г. |
| Moretti August J | A | 6595 | 3000 | 21 дек 2022 г. |
| Kirn David | D | 1913123 | 26349 | 16 дек 2022 г. |
| Kirn David | D | 1939472 | 27595 | 16 дек 2022 г. |
| Kirn David | D | 1967067 | 1500 | 15 дек 2022 г. |
| Kirn David | D | 1968567 | 31433 | 15 дек 2022 г. |
| Bizily Scott | D | 56250 | 3750 | 01 дек 2022 г. |
| Bizily Scott | D | 22125 | 1875 | 01 дек 2022 г. |
Новостная лента
4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile
Seeking Alpha
03 янв 2023 г. в 08:55
FDMT is an undercovered gene therapy developer. It claims certain competitive differences for its vector delivery platform.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
24/7 Wall Street
13 дек 2022 г. в 22:55
Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
The Motley Fool
20 ноя 2022 г. в 05:39
Recent analyst upgrades suggest these stocks can triple your money or better.
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why
Zacks Investment Research
17 ноя 2022 г. в 12:02
4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.
Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?
Zacks Investment Research
28 окт 2022 г. в 13:33
4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.